N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial–mesenchymal transition in silicotic mice

Shumin Li,Yaqian Li,Yi Zhang,Shifeng Li,Min Zhang,Fuyu Jin,Zhongqiu Wei,Yi Yang,Xuemin Gao,Na Mao,Xingchen Ge,Hong Xu,Fang Yang
DOI: https://doi.org/10.1016/j.taap.2020.115255
IF: 4.46
2020-12-01
Toxicology and Applied Pharmacology
Abstract:<p>Silicosis is a major public health concern with various contributing factors. The renin–angiotensin system (RAS)is a critical regulator in the pathogenesis of this disease. We focused on two key RAS enzymes, angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2), to elucidate the activation of the ACE–angiotensin II (Ang II)–angiotensin II receptor 1 (AT1) axis and the inhibition of the ACE2–angiotensin-(1–7) [Ang-(1–7)]-Mas receptor axis in C57BL/6mice following SiO<sub>2</sub> treatment. Silica exposure caused nodule formation, pulmonary interstitial fibrosis, epithelial–mesenchymal transition (EMT), abnormal deposition of extracellular matrix, and impaired lung function in mice. These effects were attenuated by the inhibition of ACE (captopril), blockade of the AT1(losartan), or systemic knockdown of the <em>Ace</em> gene. These effects were exacerbated by the inhibition of ACE2 (MLN-4760), blockade of the Mas (A779), or knockdown of the <em>Ace2</em> gene. N-Acetyl-Seryl-Asparyl-Lysyl-Proline (Ac-SDKP), an anti-fibrotic peptide, ameliorated the silica-exposure-induced pathological changes by targeting the RAS system by activating the protective ACE2–Ang-(1–7)–Mas axis and inhibiting the deleterious ACE–Ang II–AT1 axis, thereby exerting a protective effect. This was confirmed in mouse lung type II epithelial cells (MLE-12) pretreated with Ang II and/or gene silencing separately targeting <em>Ace</em> and <em>Ace2</em>.The effects of Ac-SDKP were similar to those produced by <em>Ace</em> gene silencing and were partly attenuated by <em>Ace2</em> deficiency. These findings suggested that RAS plays critical roles in the pathomechanism of silicosis fibrosis and that Ac-SDKP regulates lung RAS to inhibit EMT in silicotic mice and MLE-12 cells.</p>
pharmacology & pharmacy,toxicology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the mechanism of action of N - Acetyl - Seryl - Asparyl - Lysyl - Proline (Ac - SDKP) in inhibiting epithelial - mesenchymal transition (EMT) by regulating the pulmonary renin - angiotensin system (RAS) in silicotic mice. Specifically, the research aims to: 1. **Clarify the regulatory effect of Ac - SDKP on RAS**: Study how Ac - SDKP exerts its anti - fibrotic effect by activating the protective ACE2 - angiotensin - (1 - 7) - Mas receptor axis (ACE2 - Ang - (1 - 7) - Mas axis) and inhibiting the harmful ACE - angiotensin II - AT1 receptor axis (ACE - Ang II - AT1 axis). 2. **Evaluate the impact of Ac - SDKP on EMT**: Explore the specific effects of Ac - SDKP in inhibiting EMT in silicotic mice and mouse lung type II epithelial cells (MLE - 12 cells), including reducing the expressions of α - smooth muscle actin (α - SMA), vimentin, collagen I and collagen III, and increasing the expression of E - cadherin. 3. **Verify the anti - fibrotic effect of Ac - SDKP**: Through in vivo and in vitro experiments, verify the anti - fibrotic effect of Ac - SDKP in the silicosis model, including reducing the number and area of lung nodules, alleviating weight loss, and improving lung function. 4. **Explore the roles of ACE and ACE2 in silicosis**: By using mouse models with ACE gene knockdown (Ace+/−) and ACE2 gene knockdown (Ace2+/−), further study the key roles of ACE and ACE2 in the development of silicosis. Through these studies, the paper hopes to provide new ideas and potential drug targets for the treatment of silicosis.